CanSino: September Share Capital Stable Amid Incentive Plan

CanSino Biologics Inc. reported stable authorized/registered share capital as of September 30, 2025. The company held 132,670,900 H shares and 114,778,999 A shares, totaling RMB 247,449,899. Both H shares, listed on the Exchange, and A shares, listed on the STAR Market of the Shanghai Stock Exchange, had a par value of RMB 1 per share.

The company saw no increase or decrease in its issued H shares or A shares during September 2025, with totals remaining at 132,670,900 and 114,778,999 respectively. The number of treasury A shares also remained unchanged at 406,098.

These 406,098 treasury A shares, repurchased between February 7, 2022, and December 1, 2022, are held for future employee stock ownership or equity incentive schemes. No A shares were repurchased in September 2025, and any unutilized shares will be cancelled as per the board's January 23, 2022, approval for the repurchase plan.